Helicobacter and gastric malignancies

Helicobacter

Volumn 12, Issue SUPPL. 1, 2007, Pages 23-30

  Moss, Steven F ^a,c   Malfertheiner, Peter ^b  

^a BROWN UNIVERSITY   (United States)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Breast cancer; Eradication; Gastric cancer; Helicobacter pylori; MALT lymphoma

Indexed keywords

AMOXICILLIN; CYCLOOXYGENASE 2; GARLIC EXTRACT; OMEPRAZOLE; PLACEBO; ROFECOXIB;

B CELL LYMPHOMA; BACTERIAL TRANSLOCATION; BACTERIUM ADHERENCE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; ERADICATION THERAPY; GENETIC POLYMORPHISM; HELICOBACTER HEPATICUS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNE RESPONSE; INTESTINE METAPLASIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH EPITHELIUM; STOMACH LYMPHOMA; VITAMIN SUPPLEMENTATION;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; FEMALE; GASTRIC MUCOSA; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MICE; PROTEINS; STOMACH NEOPLASMS;

HELICOBACTER; HELICOBACTER HEPATICUS; HELICOBACTER PYLORI; MURINAE; MUS;

EID: 34548161677     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00539.x     Document Type: Review

References (53)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006 118 : 3030 44.
2. Palli D, Masala G, Del Giudice G, et al. CagA+ Helicobacter pylori infection and gastric cancer risk in the EPIC-EURGAST study. Int J Cancer 2007 120 : 859 67.
3. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 2006 98 : 1445 52.
4. Kamangar F, Qiao YL, Blaser MJ, et al. Helicobacter pylori and oesophageal and gastric cancers in a prospective study in China. Br J Cancer 2007 96 : 172 6.
5. Naylor GM, Gotoda T, Dixon M, Shimoda T, Gatta L, Owen R, Tompkins D, Axon A. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients. Gut 2006 55 : 1545 52.
6. Blaser MJ, Nomura A, Lee J, Stemmerman GN, Perez-Perez GI. Early-life family structure and microbially induced cancer risk. PLoS Med 2007 4 : e7.
7. Nyren O, McLaughlin JK, Gridley G, Ekbom A, Johnell O, Fraumeni JF Jr., Adami HO. Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst 1995 87 : 28 33.
8. Fall K, Ye W, Nyren O Antibiotic treatment and risk of gastric cancer. Gut 2006 55 : 793 6.
9. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006 98 : 974 83.
10. Takenaka R, Okada H, Kato J, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007 25 : 805 12.
11. Fuccio L, Zagari RM, Minardi ME, Bazzoli F. Systematic review. Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther 2007 25 : 133 41.
12. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection - The Maastricht III Consensus Report. Gut 2007.
13. Yang HB, Cheng HC, Sheu BS, Hung KH, Liou MF, Wu JJ. Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication. Aliment Pharmacol Ther 2007 25 : 455 61.
14. Leung WK, Ng EK, Chan FK, Chan WY, Chan KF, Auyeung AC, Lam CC, Lau JY, Sung JJ. Effects of long-term rofecoxib on gastric intestinal metaplasia: results of a randomized controlled trial. Clin Cancer Res 2006 12 : 4766 72.
15. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001 286 : 954 9.
16. Necchi V, Candusso ME, Tava F, Luinetti O, Ventura U, Fiocca R, Ricci V, Solcia E. Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori. Gastroenterology 2007 132 : 1009 23.
17. Oh JD, Karam SM, Gordon JI. Intracellular Helicobacter pylori in gastric epithelial progenitors. Proc Natl Acad Sci USA 2005 102 : 5186 91.
18. Yao Y, Tao H, Park DI, Sepulveda JL, Sepulveda AR. Demonstration and characterization of mutations induced by Helicobacter pylori organisms in gastric epithelial cells. Helicobacter 2006 11 : 272 86.
19. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med 2007 13 : 470 6.
20. Oh JD, Kling-Backhed H, Giannakis M, et al. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: evolution during disease progression. Proc Natl Acad Sci USA 2006 103 : 9999 10004.
21. Ellmark P, Ingvarsson J, Carlsson A, Lundin BS, Wingren C, Borrebaeck CA. Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol Cell Proteomics 2006 5 : 1638 46.
22. Lin YF, Wu MS, Chang CC, Lin SW, Lin JT, Sun YJ, Chen DS, Chow LP. Comparative immunoproteomics of identification and characterization of virulence factors from Helicobacter pylori related to gastric cancer. Mol Cell Proteomics 2006 5 : 1484 96.
23. Oliveira MJ, Costa AC, Costa AM, et al. Helicobacter pylori induces gastric epithelial cell invasion in a c-Met and type IV secretion system-dependent manner. J Biol Chem 2006 281 : 34888 96.
24. Beswick EJ, Pinchuk IV, Suarez G, Sierra JC, Reyes VE. Helicobacter pylori CagA-dependent macrophage migration inhibitory factor produced by gastric epithelial cells binds to CD74 and stimulates procarcinogenic events. J Immunol 2006 176 : 6794 801.
25. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, Price PM, Welch IM, West CM. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br J Cancer 2007 96 : 95 103.
26. Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002 109 : 113 24.
27. Friedrich MJ, Rad R, Langer R, Voland P, Hoefler H, Schmid RM, Prinz C, Gerhard M. Lack of RUNX3 regulation in human gastric cancer. J Pathol 2006 210 : 141 6.
28. Leung WK, Man EP, Yu J, Go MY, To KF, Yamaoka Y, Cheng VY, Ng EK, Sung JJ. Effects of Helicobacter pylori eradication on methylation status of E-cadherin gene in noncancerous stomach. Clin Cancer Res 2006 12 : 3216 21.
29. Nakajima T, Maekita T, Oda I, Gotoda T, Yamamoto S, Umemura S, Ichinose M, Sugimura T, Ushijima T, Saito D. Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. Cancer Epidemiol Biomarkers Prev 2006 15 : 2317 21.
30. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000 404 : 398 402.
31. Viala J, Chaput C, Boneca IG, et al. Nod1 responds to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island. Nat Immunol 2004 5 : 1166 74.
32. Rosenstiel P, Hellmig S, Hampe J, et al. Influence of polymorphisms in the NOD1/CARD4 and NOD2/CARD15 genes on the clinical outcome of Helicobacter pylori infection. Cell Microbiol 2006 8 : 1188 98.
33. Liu F, Pan K, Zhang X, et al. Genetic variants in cyclooxygenase-2. Expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006 130 : 1975 84.
34. Kubben FJ, Sier CF, Meijer MJ, van den Berg M, van der Reijden JJ, Griffioen G, van de Velde CJ, Lamers CB, Verspaget HW. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br J Cancer 2006 95 : 744 51.
35. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of Toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007 132 : 905 12.
36. Kim JS, Chung SJ, Choi YS, Cheon JH, Kim CW, Kim SG, Jung HC, Song IS. H. pylori eradication for low-grade gastric mucosa-associated lymphoid tissue lymphoma is more successful in inducing remission in distal compared to proximal disease. Br J Cancer 2007 7 : 1324 8.
37. Hong SS, et al. A prospective analysis of low-grade gastric MALT lymphoma after H. pylori eradication. Helicobacter 2006 11 : 569 73.
38. Seo DB, Kwon KS, Park HS, Lee DH, Kim HG, Shin YW, Kim YS, Kim JM. Metachronous gastric MALT lymphoma and early gastric cancer: a case report. Korean J Gastroenterol 2007 49 : 245 50.
39. Chan CC, Shen D, Mochizuki M, Gonzales J, Yuen H, Guex-Crosier Y, LeHoang P. Detection of H. pylori and Chlamydia pneumoniae genes in primary orbital lymphoma. Trans Am Ophthalmol Soc 2006 104 : 62 70.
40. Raderer M, et al. Successful antibiotic treatment of H. pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006 55 : 616 8.
41. Grünberger B, et al. Antibiotic treatment is not effective in patients infected with H. pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006 20 : 1370 5.
42. Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia 2007 21 : 389 96.
43. Bussiere FI, Chaturvedi RA, Sim M, Hoek KL, Cheng Y, Gainor J, Scholz A, Khan WN, Wilson KT. Low multiplicity of infection of H. pylori suppresses apoptosis of B lymphocytes. Cancer Res 2006 1 : 6834 42.
44. Zhu Y, Wang C, Huang J, Ge Z, Dong Q, Zhong X, Su Y, Zheng S. The H. pylori virulence factor CagA promotes Erk1/2-mediated Bad phosphorylation in lymphocytes: a mechanism of CagA-inhibited lymphocyte apoptosis. Cell Microbiol 2007 9 : 952 61.
45. Montalban C, Norman F. Treatment of gastric mucosa-associated lymphoid tissue lymphoma: H. pylori eradication and beyond. Expert Rev Anticancer Ther 2006 6 : 361 71.
46. Du MQ, Atherton JC. Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. Gut 2006 55 : 886 93.
47. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, Wang TE, Cheng AL, Wu MS. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2006 20 : 3483 9.
48. Nakamura M, Murayama SY, Serizawa H, et al. Candidatus Helicobacter heilmanii from a cynomolgus monkey induces gastric mucosa-associated lymphoid tissue lymphomas in C57BL/6 mice. Infect Immun 2007 75 : 1214 22.
49. Helmig S, Gieseler F, Ott S, Rosenstiel P, Fischbach W, Fölsch UR, Schreiber S. Germline variations of the topoisomerase alpha gene as risk factors for primary gastric B-cell lymphoma. Cancer Lett 2006 18 : 295 303.
50. Kuo SH, Chen LT, Wu MS, et al. Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expression. J Pathol 2007 211 : 296 304.
51. Nakamura S, Ye H, Bacon CM, et al. Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fluorescence in situ hybridisation. Gut (epub 24 May 2007).
52. Schmees C, Prinz C, Treptau T, Rad R, Hengst L, Voland P, Bauer S, Brenner L, Schmid RM, Gerhard M. Inhibition of T-cell proliferation by H. pylori gamma-glutamyl transpeptidase. Gastroenterology 2007 132 : 1820 33.
53. Rao VP, Poutahidis T, Ge Z, Nambiar PR, Boussahmain C, Wang YY, Horwitz BH, Fox JG, Erdman SE. Innate immune inflammatory response against enteric bacteria Helicobacter hepaticus induces mammary adenocarcinoma in mice. Cancer Res 2006 66 : 7395 400.